tbuckley/cabot-search huggingface dataset:
Abstract 1502: Gender-Specific Reversibility of Calcineurin-Induced Ventricular Remodeling
Authors: Vien Le, Paul Tannous, Jeff M Berry, Michael P Czubryt, Johannes Backs, Rhonda Bassel-Duby, Eric N Olson, Beverly A Rothermel, Joseph A Hill
Journal: Circulation (2007)

Background: Ventricular hypertrophy will sometimes reverse when the inciting stimulus (e.g. hypertension) is removed; at a certain point, however, pathological remodeling becomes irreversible. Further, recent studies have highlighted differences in disease pathogenesis triggered by signaling pathways activated in males (M) versus females (F). However, little is known regarding mechanisms of hypertrophy resolution, markers of irreversibility, or the effects of gender-specific mechanisms thereon. Methods: We engineered mice that express a constitutively active calcineurin mutant driven by a tet-off-αMHC promoter (tetCnA). During gestation, through weaning, and up to 5 wks of age, tetCnA mice were exposed to doxycycline (dox). Then, mice were randomized to dox (OFF) or dH2O (ON) for 16 wks. In the ON group, half received dH20 for 8 wks followed by dox for 8 wks (ON-OFF). Serial echocardiography was performed every 2 wks. Results: Systolic function declined significantly (p&lt;0.05) and similarly by 8 wks in all ON mice (%FS = 37% ± 2, F-ON n=6; 35% ± 8, M-ON n=6; 38% ± 7, F-ON-OFF n=5; and 35% ± 2, M-ON-OFF n=5) as compared with OFF mice (%FS = 63% ± 5, F-OFF n=6; and 68% ± 7, M-OFF n=4). After 8 wks, resumption of dox to shut off calcineurin expression led to continued declines in systolic function in male mice (%FS at 16 wks 35% ± 3, M-ON-OFF n=5), similar to M-ON (30% ± 1, M-ON n=6), suggesting that pathological remodeling was irreversible. Conversely, systolic performance recovered completely in female ON-OFF mice (%FS at 16 wks = 62% ± 4, n=5) as compared with F-ON (36% ± 5, n=6, p&lt;0.05). Necropsy at 16 wks revealed increased heart mass (p&lt;0.05) in all ON mice and male ON-OFF mice (heart weight / tibia, HW/T = 12.4 ± 1.4 mg/mm, F-ON; 12.7 ± 2.1, M-ON; 12.0 ± 0.7, M-ON-OFF) as compared with all OFF mice (7.1 ± 0.4, F-OFF; 8.1 ± 0.5, M-OFF). Remarkably, heart mass at 16 wks was similar (p=NS) in F-ON-OFF (7.9 ± 0.4, n=5) and F-OFF mice, and accumulation of interstitial fibrosis was less as compared with all other groups. Conclusions: Calcineurin activation in adolescent male mice triggers pathological remodeling that is severe and irreversible after 2 months. In contrast, similar degrees of calcineurin-induced ventricular remodeling in adolescent female mice remain reversible at 2 months.
435P The AGITG Modulate study: Randomised phase II study testing manipulation of the tumour micro environment (TME) to enable synergy with PD1 inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Authors: N.C. Tebbutt, M. Burge, C. Underhill, M. Farrell, S. Xie, A. Nagrial, N. Pavlakis, A. Strickland, G. Chong, J. Tie, R. Wong, T.J. Price
Journal: Annals of Oncology (2021)
132P Health economic properties of palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy: Results from the Penelope-B trial
Authors: K. Galactionova, S. Loibl, P. Salari, F. Marmé, M. Martin, M. Untch, H. Bonnefoi, S-B. Kim, H.D. Bear, N. McCarthy, K. Gelmon, J.A. García-Saenz, C.M. Kelly, T. Reimer, M. Toi, H.S. Rugo, M. Gnant, A. Makris, N. Burchardi, M. Schwenkglenks
Journal: Annals of Oncology (2021)
Covid grief: medical examiner’s office could be central point of access for counselling and support services
Authors: Alan J Kevern
Journal: BMJ (2021)

The covid-19 pandemic has shaken the lives of every person in virtually all aspects. We should take a moment to reflect on the impact it has had on all aspects of death, too.

Working as medical examiner during the pandemic has been a career milestone. I have painful memories of piles of notes on my desk, each with a death …
Adcitmer <sup>®</sup> , a new CD56‐targeting monomethyl auristatin E‐conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma*
Authors: C. Esnault, V. Leblond, C. Martin, A. Desgranges, C.B. Baltus, N. Aubrey, Z. Lakhrif, L. Lajoie, L. Lantier, B. Clémenceau, B. Sarma, J. Schrama, R. Houben, D. Schrama, S. Hesbacher, V. Gouilleux‐Gruart, Y. Feng, D. Dimitrov, S. Guyétant, P. Berthon, M.C. Viaud‐Massuard, M. Samimi, A. Touzé, T. Kervarrec
Journal: British Journal of Dermatology (2021)

Background Merkel cell carcinoma (MCC) is an aggressive skin cancer, whose tumour cells often express CD56. While immune checkpoint inhibitors constitute a major advance for treating patients with MCC with advanced disease, new therapeutic options are still urgently required. Objectives To produce and evaluate the therapeutic performance of a new antibody–drug conjugate (Adcitmer®) targeting CD56 in preclinical models of MCC. Methods CD56 expression was evaluated in a MCC cohort (immunohistochemistry on a tissue microarray of 90 tumour samples) and MCC cell lines. Interaction of an unconjugated CD56-targeting antibody with CD56+ MCC cell lines was investigated by immunohistochemistry and imaging flow cytometry. Adcitmer® product was generated by the bioconjugation of CD56-targeting antibody to a cytotoxic drug (monomethyl auristatin E) using the McSAF Inside® bioconjugation process. The chemical properties and homogeneity of Adcitmer® were characterized by hydrophobic interaction chromatography. Adcitmer® cytotoxicity was evaluated in vitro and in an MCC xenograft mice model. Results Similar to previous reports, CD56 was expressed by 66% of MCC tumours in our cohort, confirming its relevance as a therapeutic target. Specific binding and internalization of the unconjugated CD56-targeting antibody was validated in MCC cell lines. The high homogeneity of the newly generated Adcitmer® was confirmed by hydrophobic interaction chromatography. The CD56-mediated cytotoxicity of Adcitmer® was demonstrated in vitro in MCC cell lines. Moreover, Adcitmer® significantly reduced tumour growth in a MCC mouse model. Conclusions Our study suggests that Adcitmer® should be further assessed as a therapeutic option in patients with MCC, as an alternative therapy or combined with immune checkpoint inhibitors.
1285P Final analysis of TORG1936/AMBITIOUS: Phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonia
Authors: Y. Sato, S. Ikeda, T. Kato, H. Kenmotsu, T. Ogura, A. Hino, T. Harada, K. Kubota, T. Tokito, I. Okamoto, N. Furuya, T. Yokoyama, S. Hosokawa, T. Iwasawa, R. Kasajima, Y. Miyagi, T. Misumi, T. Yamanaka, H. Okamoto
Journal: Annals of Oncology (2021)
869P Nivolumab (Nivo) and ipilimumab (Ipi) combined with radiotherapy (RT) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): Updated results of a pilot study
Authors: J.M. Johnson, A. Ali, E. Lorber, D. Poller, S.W. Keith, A. Luginbuhl, J.M. Curry, D. Cognetti, R. Axelrod, V. Bar-Ad, A. Argiris
Journal: Annals of Oncology (2021)
A new piece in the puzzle: the eosinophil and the development of COPD
Authors: Nayia Petousi, Abigail Wooden, Richard E.K. Russell
Journal: European Respiratory Journal (2021)

<b>A large prospective population study has clearly demonstrated that blood eosinophils predict the development of airflow obstruction. This insight leads to the potential for early targeted intervention to prevent this happening.</b>https://bit.ly/3vk7mBu
905P FIH phase I dose escalation and dose expansion study of anti-EGFR ADC MRG003 in patients with advanced solid tumors
Authors: M. Qiu, Y. Guo, W. Guo, W. Nian, W. Liao, Z. Xu, W. Zhang, Y. Zhang, X. Wei, L. Xue, W. Tang, Y. Wu, G. Ren, L. Wang, J. Xi, Y. Wang, M. Li, F. Hausheer, C. Hu, R. Xu
Journal: Annals of Oncology (2021)
Obesity and Gα <sub>s</sub> Variants
Authors: Harald Jüppner
Journal: New England Journal of Medicine (2021)

Mendes de Oliveira and colleagues now report in the Journal that variants in GNAS exons that encode the stimulatory G-protein alpha subunit (Gαs) have a strong genetic association with severe obesity, owing to reduced signaling by the melanocortin 4 receptor (MC4R) and possible signaling abnormalities at other G protein–coupled receptors (GPCRs).1 Given the multitude of biologic functions mediated by Gαs, which is best known among the various GNAS-derived transcripts and proteins, and the well-established clinical and laboratory abnormalities encountered in pseudohypoparathyroidism type 1a and 1b (PHP1A and PHP1B, respectively), these exciting findings are not entirely unexpected. Gαs serves a diverse . . .
5MO CDK4/6 blockade is as effective as immune-checkpoint inhibition in tumor growth control of Mlh1-/- and Msh2loxP/loxP villin-Cre mice
Authors: I. Salewski, L. Engster, J. Henne, L. Henze, C. Junghanss, C. Maletzki
Journal: Annals of Oncology (2021)
55P Integrative genomic analysis identified primary cilium-associated genes by as novel key genes in biliary tract cancer (BTC)
Authors: M. Salati, A. Barbato, F. Luigi, I. Antonella, G. Gennaro, F. Brunella, M. Salatiello, G. Troncone, R.B. Luca, M. Dominici, P. Carotenuto
Journal: Annals of Oncology (2021)
1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19?
Authors: G.M. Iannantuono, F. Torino, L. Strigari, B. Capotondi, F. Dell'Aria, V. Flaminio, S. Guerriero, G. Parisi, R. Rosenfeld, F. Amodio, B. Creso, L. Filomeno, F. Mastrobattista, A. Meacci, F.E. Palumbo, L. Santurri, S. Sganga, M. Roselli
Journal: Annals of Oncology (2021)
1459P A comparative study on the effect of palliative care between palliative care team and medical oncologists in patients with advanced cancer at Phramongkutklao Hospital
Authors: P. Pornrattanakavee, N. Prasongsook, S. Saichaemchan, K. Seetalarom, N. Oer-areemitr, T. Srichan
Journal: Annals of Oncology (2021)
MicroRNA‐206 enhances antitumor immunity by disrupting the communication between malignant hepatocytes and regulatory T cells in c‐Myc mice
Authors: Ningning Liu, Clifford J. Steer, Guisheng Song
Journal: Hepatology (2021)

Abstract Background and Aims Intertumoral accumulation of regulatory T cells (Tregs) has been implicated in the pathogenesis of HCC. Because of poor understanding of the immunosuppression mechanism(s) in HCC, immunotherapy is largely unsuccessful for the treatment of HCC. Approach and Results Hydrodynamic injection (HDI) of c‐Myc into mice resulted in enlarged spleens and lethal HCC associated with an increase in hepatic Tregs and depletion of CTLs (cytotoxic T lymphocytes). Malignant hepatocytes in c‐Myc mice overproduced TGFβ1, which enhanced the suppressor function of Tregs and impaired the proliferation and cytotoxicity of CTLs. In addition to activating TGFβ signaling, c‐Myc synergized with Yin Yang 1 to impair microRNA‐206 (miR‐206) biogenesis. HDI of miR‐206 fully prevented HCC and the associated enlargement of the spleen, whereas 100% of control mice died from HCC within 5‐9 weeks postinjection. Mechanistically, by directly targeting errant kirsten ras oncogene (KRAS) signaling, miR‐206 impeded the mitogen‐activated protein kinase kinase (MEK)/extracellular signal‐regulated kinase (ERK) axis that drives expression of Tgfb1 . By blocking the KRAS/MEK/ERK axis, miR‐206 prevented TGFβ1 overproduction, thereby impairing the suppressor function and expansion of Tregs, but enhancing the expansion and cytotoxic program of CTLs. Disrupting the interaction between miR‐206 and Kras offset the roles of miR‐206 in inhibiting immunosuppression and HCC. Depletion of CD8 + T cells impaired the ability of miR‐206 to inhibit HCC. Conclusions c‐Myc‐educated hepatocytes promoted immunosuppression by overproducing TGFβ1, which promoted HCC development. miR‐206, by attenuating TGFβ1 overproduction, disrupted the communication of malignant hepatocytes with CTLs and Tregs, which prevented HCC. miR‐206 represents a potential immunotherapeutic agent against HCC.
1826P Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: A global survey
Authors: T. Cufer, M. Kosty, P.J. Osterlund, S. Jezdic, D. Pyle, A. Awada, J. Close, N. El-Saghir, F. Lordick, P. Rutkowski, A. Tfayli, H. Wildiers
Journal: Annals of Oncology (2021)
1188P Concurrent chemoradiotherapy with cisplatin + S-1 for locally advanced non-small cell lung cancer: IPD meta-analysis
Authors: Y. Taniguchi, H. Okamoto, T. Shimokawa, T. Sasaki, T. Seto, S. Niho, Y. Ohe, Y. Saigusa, T. Yamanaka
Journal: Annals of Oncology (2021)
145P High-risk breast cancer patients with RAD51-low tumors are characterized by good prognosis
Authors: B. Pellegrino, A. Llop-Guevara, N. Campanini, C. Tommasi, G. Villacampa Javierre, F. Pedretti, B. Bortesi, R. Minari, E. Rapacchi, M. Michiara, D. Boggiani, A. Sikokis, D. Zanoni, E.M. Silini, V. Serra, A. Musolino
Journal: Annals of Oncology (2021)
551P Chronological improvement in precision oncology implementation in Japan
Authors: K. Komine, K. Sunami, Y. Naito, T. Amano, D. Ennishi, M. Imai, H. Kage, M. Kanai, H. Kenmotsu, T. Koyama, Maeda T., S. Morita, D. Sakai, S. Kohsaka, K. Tsuchihara, Y. Saigusa, T. Yamanaka, T. Yoshino
Journal: Annals of Oncology (2021)
492P Vitamin D deficiency in metastatic colorectal cancer (mCRC) worsens survival and correlates with significant peripheral inflammatory/immune cell changes
Authors: M. Rofei, C. Morelli, S. Riondino, S. Guerriero, G. Parisi, S. Braudo, D. Nitti, P. Ferroni, F. Guadagni, D. Fraboni, A. Orlandi, V. Formica, M. Roselli
Journal: Annals of Oncology (2021)
Abstract 14254: Cardiac Manifestations of Leptospirosis: Insights From a Large Southern India Prospective Cohort
Authors: Anoop Mathew, Miriam Shanks, Eapen Punnoose, Louie Fischer, George Koshy, Kevin R Bainey
Journal: Circulation (2018)

Introduction: Myocardial inflammation often complicates leptospirosis, a re-emerging global zoonosis. However, there is limited clinical data on the cardiac manifestations of leptospirosis. Hypothe...
<i>Selenomonas</i>: A marker of asthma severity with the potential therapeutic effect
Authors: Young‐Chan Kim, Sungmi Choi, Kyoung‐Hee Sohn, Ji‐Young Bang, Yuldam Kim, Jae‐Woo Jung, Hye‐Young Kim, Jaehyun Park, Kangjin Kim, Min‐Gyu Kang, Min‐Suk Yang, Sujeong Kim, Sae‐Hoon Kim, Jeong‐Hee Choi, Hye Jung Park, Sang Min Lee, Sang Heon Kim, Jung‐Won Park, Jong Myung Lee, Sang‐Heon Cho, Sungho Won, Hana Yi, Hye‐Ryun Kang
Journal: Allergy (2021)
526P Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3
Authors: P. Chalasani, A. Tolcher, F. Meric-Bernstam, H. Mamdani, P.R. de Jong, K. Anderes, A.A. Samatar, M. Sergeeva, M. Gazdoiu, M.R. Viana, P. Pultar, D. Voliotis, F. Donate
Journal: Annals of Oncology (2021)
Circulating Tumor DNA in Lymphoma: Principles and Future Directions
Authors: Mark Roschewski, Davide Rossi, David M. Kurtz, Ash A. Alizadeh, Wyndham H. Wilson
Journal: Blood Cancer Discovery (2021)

Lymphomas are heterogeneous tumors with striking genetic diversity and variable outcomes even within pathologic diagnoses. Treatment response assessment relies on radiologic and nuclear scans, which cannot detect disease at the molecular level. Molecular tumor analyses require invasive tissue biopsies that cannot accurately capture spatial tumor heterogeneity within each patient. Circulating tumor DNA (ctDNA) is a minimally invasive and highly versatile biomarker that overcomes fundamental limitations of imaging scans and tissue biopsies and may aid clinical decision-making in lymphoma. In this review, we highlight the key established principles regarding ctDNA in lymphoma and emphasize the important research questions and future directions. SIGNIFICANCE: ctDNA is an emerging biomarker for lymphomas that noninvasively provides genotypic information and can measure the effectiveness of treatment by detecting the presence of minimal residual disease. Key principles have emerged related to ctDNA for lymphoma, but further studies are needed to standardize its use and establish clinical utility.
1801MO Neutrophils are associated with resistance to anti-PD-1 monotherapy in mismatch repair-deficient tumors
Authors: L. Nebot-Bral, A. Yurchenko, S. Aoufouchi, L. De Forceville, M. Danjou, J-Y. Scoazec, P. Vuagnat, C. Smolenschi, A. Marabelle, S. Nikolaev, A. Hollebecque, N. Chaput, P.L. Kannouche
Journal: Annals of Oncology (2021)
Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta
Authors: Fadi Rofo, Jos Buijs, Ronny Falk, Ken Honek, Lars Lannfelt, Anna M. Lilja, Nicole G. Metzendorf, Tobias Gustavsson, Dag Sehlin, Linda Söderberg, Greta Hultqvist
Journal: Translational Neurodegeneration (2021)

Amyloid-β (Aβ) immunotherapy is a promising therapeutic strategy in the fight against Alzheimer's disease (AD). A number of monoclonal antibodies have entered clinical trials for AD. Some of them have failed due to the lack of efficacy or side-effects, two antibodies are currently in phase 3, and one has been approved by FDA. The soluble intermediate aggregated species of Aβ, termed oligomers and protofibrils, are believed to be key pathogenic forms, responsible for synaptic and neuronal degeneration in AD. Therefore, antibodies that can strongly and selectively bind to these soluble intermediate aggregates are of great diagnostic and therapeutic interest.We designed and recombinantly produced a hexavalent antibody based on mAb158, an Aβ protofibril-selective antibody. The humanized version of mAb158, lecanemab (BAN2401), is currently in phase 3 clinical trials for the treatment of AD. The new designs involved recombinantly fusing single-chain fragment variables to the N-terminal ends of mAb158 antibody. Real-time interaction analysis with LigandTracer and surface plasmon resonance were used to evaluate the kinetic binding properties of the generated antibodies to Aβ protofibrils. Different ELISA setups were applied to demonstrate the binding strength of the hexavalent antibody to Aβ aggregates of different sizes. Finally, the ability of the antibodies to protect cells from Aβ-induced effects was evaluated by MTT assay.Using real-time interaction analysis with LigandTracer, the hexavalent design promoted a 40-times enhanced binding with avidity to protofibrils, and most of the added binding strength was attributed to the reduced rate of dissociation. Furthermore, ELISA experiments demonstrated that the hexavalent design also had strong binding to small oligomers, while retaining weak and intermediate binding to monomers and insoluble fibrils. The hexavalent antibody also reduced cell death induced by a mixture of soluble Aβ aggregates.We provide a new antibody design with increased valency to promote binding avidity to an enhanced range of sizes of Aβ aggregates. This approach should be general and work for any aggregated protein or repetitive target.
228MO PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)
Authors: B. Xu, X. Hu, W. Li, T. Sun, K. Shen, S. Wang, Y. Cheng, Q. Zhang, S. Cui, Z. Tong, C. Geng, C-S. Huang, V. Sriuranpong, K.C.R. Ngan, Y.H. Chia, X. Wang, H. Zhao
Journal: Annals of Oncology (2021)
Compared to What?—Novel Methods to Approach Randomization for Long-term Bariatric Surgery Outcomes
Authors: Anita P. Courcoulas, Bestoun Ahmed
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
1401P Findings and survival comparison of EUS and PET-TC restaging applied to esophageal and gastric adenocarcinomas
Authors: V. Amezcua Hernandez, K. Doello González, J.G. Martínez-Cara, R. Jiménez-Rosales, F. Valverde-López, J.A. Garcia-Garcia, E. Redondo-Cerezo
Journal: Annals of Oncology (2021)
1339P Efficacy and safety of MIL60, a bevacizumab biosimilar, in combination with paclitaxel/carboplatin in patients with advanced or recurrent non-squamous non-small cell lung cancer: A randomized, double-blind, multicenter phase III study
Authors: J. Wang, R. Wang, X. Dong, Q. Chen, Y. Yu, S. Yang, X. Zhang, G. Zhang, Y. Pan, S. Sun, C. Zhou, W. Hong, H. Zhao, L. Yang, L. Huang, R. Wu, A. Zang, R. Ma, L. Wu, D. Lv
Journal: Annals of Oncology (2021)
1072P Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome
Authors: E. Cocorocchio, L. Nezi, S. Gandini, T. Manzo, L. Mazzarella, F. Lotti, L. Pala, P. Gnagnarella, F. Conforti, E. Pennacchioli, M.T. Fierro, S. Ribero, R. Senetta, F. Picciotto, V. Caliendo, P. Quaglino, G. Mazzarol, G.M. Orsolini, P. Prestianni, P.F. Ferrucci
Journal: Annals of Oncology (2021)
Ultrathin 2D Titanium Carbide MXene (Ti<sub>3</sub>C<sub>2</sub>T<i><sub>x</sub></i>) Nanoflakes Activate WNT/HIF‐1<i>α</i>‐Mediated Metabolism Reprogramming for Periodontal Regeneration
Authors: Di Cui, Na Kong, Liang Ding, Yachong Guo, Wenrong Yang, Fuhua Yan
Journal: Advanced Healthcare Materials (2021)

Periodontal defect regeneration in severe periodontitis relies on the differentiation and proliferation of periodontal ligament cells (PDLCs). Recently, an emerging 2D nanomaterial, MXene (Ti
The evolution of music as artistic cultural innovation expressing intuitive thought symbolically
Authors: Valerie van Mulukom
Journal: Behavioral and Brain Sciences (2021)

Abstract Music is an artistic cultural innovation, and therefore it may be considered as intuitive thought expressed in symbols, which can efficiently convey multiple meanings in learning, thinking, and transmission, selected for and passed on through cultural evolution. The symbolic system has personal adaptive benefits besides social ones, which should not be overlooked even if music may tend more to the latter.
Harnessing novel engineered feeder cells expressing activating molecules for optimal expansion of NK cells with potent antitumor activity
Authors: Bokyung Min, Bitna Yang, You-Sun Kim, Gyeong Min Park, HyunAh Kim, Hyojin Kim, Eun-Ji Kim, Yu Kyeong Hwang, Eui-Cheol Shin, Sungyoo Cho
Journal: Cellular and Molecular Immunology (2021)